Published in Ann Rheum Dis on September 12, 2012
The kidneys and ANCA-associated vasculitis: from pathogenesis to diagnosis. Clin Kidney J (2015) 0.88
Biomarkers in vasculitis. Curr Opin Rheumatol (2014) 0.86
Pulmonary renal syndrome in a patient with vasculitis: Case report and review of literature. Pak J Med Sci (2016) 0.83
Peripheral blood natural killer cell percentages in granulomatosis with polyangiitis correlate with disease inactivity and stage. Arthritis Res Ther (2015) 0.79
Regulation of serum matrix metalloproteinases and tissue inhibitor of metalloproteinases-1 following rituximab therapy in patients with rheumatoid arthritis refractory to anti-tumor necrosis factor blockers. Rheumatol Int (2014) 0.77
Active but not inactive granulomatosis with polyangiitis is associated with decreased and phenotypically and functionally altered CD56(dim) natural killer cells. Arthritis Res Ther (2016) 0.75
Current and novel biomarkers in anti-neutrophil cytoplasm-associated vasculitis. Clin Kidney J (2016) 0.75
The prognostic significance of the Birmingham Vasculitis Activity Score (BVAS) with systemic vasculitis patients transferred to the intensive care unit (ICU). Medicine (Baltimore) (2016) 0.75
Coming of Age--CC Chemokine Ligand 18 in ANCA-Associated Vasculitis. J Am Soc Nephrol (2015) 0.75
Targeted proteomics reveals promising biomarkers of disease activity and organ involvement in antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Res Ther (2017) 0.75
Re-Examining Neutrophil Participation in GN. J Am Soc Nephrol (2017) 0.75
The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology (1982) 79.76
A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology (1983) 30.77
Index for rating diagnostic tests. Cancer (1950) 27.09
Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med (2010) 11.05
A disease-specific activity index for Wegener's granulomatosis: modification of the Birmingham Vasculitis Activity Score. International Network for the Study of the Systemic Vasculitides (INSSYS). Arthritis Rheum (2001) 3.15
Classification of osteoarthritis biomarkers: a proposed approach. Osteoarthritis Cartilage (2006) 3.10
Limited prognostic value of changes in antineutrophil cytoplasmic antibody titer in patients with Wegener's granulomatosis. Arthritis Rheum (1993) 2.14
The impact of CCR7 and CXCR5 on lymphoid organ development and systemic immunity. Immunol Rev (2003) 1.79
Prediction of relapses in Wegener's granulomatosis by measurement of antineutrophil cytoplasmic antibody levels: a prospective study. Arthritis Rheum (2000) 1.74
Antiproteinase 3 antineutrophil cytoplasmic antibodies and disease activity in Wegener granulomatosis. Ann Intern Med (2007) 1.73
Increased matrix metalloproteinase-3 serum levels in rheumatic diseases: relationship with synovitis and steroid treatment. Ann Rheum Dis (2002) 1.48
Elevated serum levels of soluble interleukin-2 receptor in patients with Wegener's granulomatosis. Association with disease activity. Arthritis Rheum (1992) 1.44
Biomarker method validation in anticancer drug development. Br J Pharmacol (2007) 1.41
Accelerated atherosclerosis in patients with Wegener's granulomatosis. Ann Rheum Dis (2004) 1.38
Objective monitoring of activity in Wegener's granulomatosis by measurement of serum C-reactive protein concentration. Clin Nephrol (1984) 1.36
Serum levels of the homeostatic B cell chemokine, CXCL13, are elevated during HIV infection. J Interferon Cytokine Res (2005) 1.32
Monocyte activation in patients with Wegener's granulomatosis. Ann Rheum Dis (1999) 1.31
Serum MMP-8, -9 and TIMP-1 in sepsis: high serum levels of MMP-8 and TIMP-1 are associated with fatal outcome in a multicentre, prospective cohort study. Hypothetical impact of tetracyclines. Pharmacol Res (2011) 1.21
Elevated production of B cell chemokine CXCL13 is correlated with systemic lupus erythematosus disease activity. J Clin Immunol (2009) 1.16
Increased circulating levels of proteinase 3 in patients with anti-neutrophilic cytoplasmic autoantibodies-associated systemic vasculitis in remission. Clin Exp Immunol (2003) 1.13
Matrix metalloproteinases as novel disease markers in Takayasu arteritis. Circulation (2003) 1.09
Serum levels of soluble adhesion molecules intercellular adhesion molecule 1, vascular cell adhesion molecule 1, and E-selectin in patients with Wegener's granulomatosis. Relationship to disease activity and relevance during followup. Arthritis Rheum (1994) 1.07
B-cell-attracting chemokine CXCL13 as a marker of disease activity and renal involvement in systemic lupus erythematosus (SLE). Nephrol Dial Transplant (2009) 1.06
Circulating cytokine profile in anti-neutrophilic cytoplasmatic autoantibody-associated vasculitis: prediction of outcome? Mediators Inflamm (2004) 1.05
Serum levels of CXCL13 are elevated in active multiple sclerosis. Mult Scler (2009) 1.01
Circulating adhesion molecules ICAM-1, VCAM-1 and E-selectin in systemic vasculitis: marked differences between Wegener's granulomatosis and systemic lupus erythematosus. Clin Investig (1994) 1.01
Are antineutrophil cytoplasmic antibodies a marker predictive of relapse in Wegener's granulomatosis? A prospective study. Rheumatology (Oxford) (2001) 1.00
Reappraisal of OMERACT 8 draft validation criteria for a soluble biomarker reflecting structural damage endpoints in rheumatoid arthritis, psoriatic arthritis, and spondyloarthritis: the OMERACT 9 v2 criteria. J Rheumatol (2009) 1.00
Serial measurements of antineutrophil cytoplasmic autoantibodies in patients with systemic vasculitis. Am J Med (1999) 1.00
Circulating markers of vascular injury and angiogenesis in antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum (2011) 0.96
CCL17/thymus and activation-related chemokine in Churg-Strauss syndrome. Arthritis Rheum (2010) 0.95
Use of highly sensitive C-reactive protein for followup of Wegener's granulomatosis. J Rheumatol (2010) 0.95
Lessons learnt in the management of Wegener's Granulomatosis: long-term follow-up of 60 patients. Rhinology (2007) 0.93
Relationship between markers of platelet activation and inflammation with disease activity in Wegener's granulomatosis. J Rheumatol (2011) 0.89
Serum levels of soluble adhesion molecules ICAM-1, VCAM-1 and E-selectin in patients with Wegener's granulomatosis. Auris Nasus Larynx (2001) 0.87
Serum concentrations of neopterin, soluble interleukin 2 receptor, and soluble tumor necrosis factor receptor in Wegener's granulomatosis. J Rheumatol (1997) 0.86
Increased levels of BLyS and sVCAM-1 in anti-neutrophil cytoplasmatic antibody (ANCA)-associated vasculitides (AAV). Clin Exp Rheumatol (2010) 0.85
Soluble cytokine receptors in renal vasculitis and lupus nephritis. Med Sci Monit (2002) 0.84
Circulating soluble adhesion molecules in ANCA-associated vasculitis. Nephrol Dial Transplant (2001) 0.83
Building multi-marker algorithms for disease prediction-the role of correlations among markers. Biomark Insights (2011) 0.83
Expression of matrix metalloproteinases in patients with Wegener's granulomatosis. Ann Rheum Dis (2004) 0.83
Increased expression of chemokines in patients with Wegener's granulomatosis - modulating effects of methylprednisolone in vitro. Clin Exp Immunol (2005) 0.82
Test result variation and the quality of evidence-based clinical guidelines. Clin Chim Acta (2004) 0.82
Interleukin-18 binding protein in the sera of patients with Wegener's granulomatosis. J Clin Immunol (2008) 0.81
Lymphocyte activation markers and von Willebrand factor antigen in Wegener's granulomatosis: potential markers for disease activity. J Rheumatol (1999) 0.80
Impact of methylprednisolone treatment on the expression of macrophage inflammatory protein 3alpha and B lymphocyte chemoattractant in serum of multiple sclerosis patients. Pharmacol Rep (2008) 0.80
Tumour necrosis factor-alpha (TNF), lymphotoxin and TNF receptor levels in serum from patients with Wegener's granulomatosis. APMIS (2001) 0.79
Screening of serum samples from Wegener's granulomatosis patients using antibody microarrays. Proteomics Clin Appl (2007) 0.79
Serum concentration of interleukin-18 is up-regulated in patients with ANCA-associated vasculitis. Autoimmunity (2007) 0.78
Osteopontin in antineutrophil cytoplasmic autoantibody-associated vasculitis: relation to disease activity, organ manifestation and immunosuppressive therapy. Ann Rheum Dis (2010) 0.77
Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I. Arthritis Rheum (2008) 13.08
Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med (2010) 11.05
Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies. Science (2005) 9.04
Consensus statement on the pathology of IgG4-related disease. Mod Pathol (2012) 9.01
The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification. Kidney Int (2009) 7.45
The Oxford classification of IgA nephropathy: pathology definitions, correlations, and reproducibility. Kidney Int (2009) 7.19
Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum (2012) 6.85
2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative. Arthritis Rheum (2013) 5.99
Efficacy of remission-induction regimens for ANCA-associated vasculitis. N Engl J Med (2013) 5.67
Generation of C5a in the absence of C3: a new complement activation pathway. Nat Med (2006) 5.26
Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum (2012) 4.80
Characterization of a rare IL-10-competent B-cell subset in humans that parallels mouse regulatory B10 cells. Blood (2010) 4.28
Brief Report: spuriously low serum IgG4 concentrations caused by the prozone phenomenon in patients with IgG4-related disease. Arthritis Rheumatol (2014) 4.18
Headache in systemic lupus erythematosus: results from a prospective, international inception cohort study. Arthritis Rheum (2013) 4.02
A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the treatment of Early Aggressive Rheumatoid Arthritis Trial. Arthritis Rheum (2012) 4.01
Proteome-wide analysis and CXCL4 as a biomarker in systemic sclerosis. N Engl J Med (2013) 3.81
Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: a randomized trial. Ann Intern Med (2007) 3.81
Granulomatosis with polyangiitis (Wegener's): an alternative name for Wegener's granulomatosis. Arthritis Rheum (2011) 3.60
A multicenter, randomized, double-blind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis. Arthritis Rheum (2002) 3.55
Pneumocystis pneumonia in patients treated with rituximab. Chest (2013) 3.48
Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum (2005) 3.35
Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: results from the ASPIRE trial. Arthritis Rheum (2006) 3.29
2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative. Ann Rheum Dis (2013) 3.11
Soy isoflavones in the prevention of menopausal bone loss and menopausal symptoms: a randomized, double-blind trial. Arch Intern Med (2011) 3.11
C3 glomerulonephritis: clinicopathological findings, complement abnormalities, glomerular proteomic profile, treatment, and follow-up. Kidney Int (2012) 3.05
Rituximab for refractory Wegener's granulomatosis: report of a prospective, open-label pilot trial. Am J Respir Crit Care Med (2005) 3.04
A clinical overview of IgG4-related systemic disease. Curr Opin Rheumatol (2011) 2.93
Clinical research for rare disease: opportunities, challenges, and solutions. Mol Genet Metab (2008) 2.91
Rituximab therapy leads to rapid decline of serum IgG4 levels and prompt clinical improvement in IgG4-related systemic disease. Arthritis Rheum (2010) 2.90
B-lymphocyte contributions to human autoimmune disease. Immunol Rev (2008) 2.89
C3 glomerulopathy: consensus report. Kidney Int (2013) 2.85
Rituximab for the treatment of IgG4-related disease: lessons from 10 consecutive patients. Medicine (Baltimore) (2012) 2.84
Recombinant human anti-transforming growth factor beta1 antibody therapy in systemic sclerosis: a multicenter, randomized, placebo-controlled phase I/II trial of CAT-192. Arthritis Rheum (2007) 2.80
Risk for cardiovascular disease early and late after a diagnosis of giant-cell arteritis: a cohort study. Ann Intern Med (2014) 2.76
Rituximab-induced depletion of anti-PLA2R autoantibodies predicts response in membranous nephropathy. J Am Soc Nephrol (2011) 2.72
Membranoproliferative glomerulonephritis--a new look at an old entity. N Engl J Med (2012) 2.67
Data standards in clinical research: gaps, overlaps, challenges and future directions. J Am Med Inform Assoc (2007) 2.64
The Environmental Determinants of Diabetes in the Young (TEDDY): genetic criteria and international diabetes risk screening of 421 000 infants. Pediatr Diabetes (2011) 2.44
Limitations of therapy and a guarded prognosis in an American cohort of Takayasu arteritis patients. Arthritis Rheum (2007) 2.38
Treatment of primary Sjögren syndrome: a systematic review. JAMA (2010) 2.37
EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis. Ann Rheum Dis (2006) 2.35
Utility of erythrocyte sedimentation rate and C-reactive protein for the diagnosis of giant cell arteritis. Semin Arthritis Rheum (2011) 2.31
Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial. Ann Rheum Dis (2010) 2.30
B cell depletion with rituximab in patients with diffuse cutaneous systemic sclerosis. Arthritis Rheum (2009) 2.26
Antiplatelet and anticoagulant therapy in patients with giant cell arteritis. Arthritis Rheum (2006) 2.26
Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis (2012) 2.21
Pulmonary necrotizing granulomas of unknown cause: clinical and pathologic analysis of 131 patients with completely resected nodules. Chest (2013) 2.21
Refractory relapsing polychondritis treated with serial success with interleukin 6 receptor blockade. J Rheumatol (2013) 2.17
Association of granulomatosis with polyangiitis (Wegener's) with HLA-DPB1*04 and SEMA6A gene variants: evidence from genome-wide analysis. Arthritis Rheum (2013) 2.17
The antineutrophil cytoplasmic antibody-associated vasculitides. Am J Med (2004) 2.16
The Oxford IgA nephropathy clinicopathological classification is valid for children as well as adults. Kidney Int (2010) 2.14
Functionally defective germline variants of sialic acid acetylesterase in autoimmunity. Nature (2010) 2.10
Urine but not serum soluble urokinase receptor (suPAR) may identify cases of recurrent FSGS in kidney transplant candidates. Transplantation (2013) 2.10
Case records of the Massachusetts General Hospital. Case 18-2014. A 32-Year-old man with a rash, myalgia, and weakness. N Engl J Med (2014) 2.09
Rituximab with or without a conventional maintenance agent in the treatment of relapsing granulomatosis with polyangiitis (Wegener's): a retrospective single-center study. Arthritis Rheumatol (2014) 2.08